A recent study suggests that glucagon-like peptide 1 receptor agonists, drugs used to treat type 2 diabetes and obesity, may also be effective in preventing Alzheimer’s disease (AD). In a real-world analysis, adults with type 2 diabetes taking the drug semaglutide had a significantly lower risk of developing AD compared to those taking other antidiabetic medications. Animal studies have shown that semaglutide has neuroprotective effects on neurodegenerative diseases. However, further clinical trials are needed to confirm these findings and determine the drug’s effectiveness in preventing AD. The Alzheimer’s Association stresses the need for more research before recommending semaglutide for AD prevention.
Source link
More Evidence Ties Semaglutide to Reduced Alzheimer’s Risk
